The medium term support area around 38.84 USD should allow Halozyme Therapeutics, Inc. shares to re-establish an upward trend in the short term. Investors have an opportunity to buy the stock and target the $ 49.9.
The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
For a short-term investment strategy, the company has poor fundamentals.
According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
The group's activity appears highly profitable thanks to its outperforming net margins.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Over the last twelve months, the sales forecast has been frequently revised upwards.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Based on current prices, the company has particularly high valuation levels.
For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.